Never before has the pharmaceutical industry faced greater challenges than now, as the whole world is looking to science for a solution to the COVID-19 global pandemic that can allow our societies to function once more. Much of this focus is naturally on the country that has been forcing back the boundaries of medicine like no other. The US is undoubtedly the world leader in bringing innovative therapeutics to market, and novel technologies currently being developed and commercialized are at record levels. An effective response to the COVID-19 pandemic requires unprecedented collaboration across academia, the private sector, and the philanthropic community. These are all areas in which the country excels. America, and in particular its leading clusters on the east coast, has a university system that is the envy of the world, as well as tech transfer, large pharma, fast growing biotech, important corporate partnerships, a well functioning incubator system, and an abundance of talent, skills and know-how regarding discovery, clinical trials and commercialization. These qualities, along with access to liquid and efficient capital markets, power the engine of the US biopharma industry.